Related references
Note: Only part of the references are listed.Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone et al.
JOURNAL OF RHEUMATOLOGY (2018)
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
H. Nakagawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)
M. de Bruin-Weller et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis
Carsten R. Hamann et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway
Daniel A. Yanes et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
New therapies for atopic dermatitis: Additional treatment classes
Paras P. Vakharia et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Emerging therapies for atopic dermatitis: TRPV1 antagonists
Jonathan G. Bonchak et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Phosphodiesterase 4 inhibitors
Rema Zebda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Emerging therapies for atopic dermatitis: JAK inhibitors
David G. Cotter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
T-cell inhibitors for atopic dermatitis
W. James Tidwell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dupilumab for treatment of atopic dermatitis
Marlene Seegraeber et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study
Robert Bissonnette et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis
Vic Ciaravino et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Interleukin-31 pathway and its role in atopic dermatitis: a systematic review
Mohammed D. Saleem et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Atopic Dermatitis in Adults: A Diagnostic Challenge
Silvestre J. F. Salvador et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2017)
Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans
Susan H. Smith et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
B. Popovic et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Brooke Rothstein et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Thomas Ruzicka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Atopic dermatitis: emerging therapies
Eric Simpson et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2017)
Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis
Gaku Tsuji et al.
CELL DEATH & DISEASE (2017)
Emerging Treatment Options in Atopic Dermatitis: Topical Therapies
Uffe Nygaard et al.
DERMATOLOGY (2017)
Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies
Uffe Nygaard et al.
DERMATOLOGY (2017)
The Alarmins HMBG1 and IL-33 Downregulate Structural Skin Barrier Proteins and Impair Epidermal Growth
Uffe Nygaard et al.
ACTA DERMATO-VENEREOLOGICA (2017)
Systemic Treatment of Adult Atopic Dermatitis: A Review
Matteo Megna et al.
DERMATOLOGY AND THERAPY (2017)
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Nicholas K. Mollanazar et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2016)
Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis
Fuminori Ohba et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial
Osamu Nemoto et al.
JOURNAL OF DERMATOLOGY (2016)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Targeting cytokine signaling in autoimmunity: back to the future and beyond
Kiyoshi Hirahara et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study
Fuminori Ohba et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka et al.
JOURNAL OF RHEUMATOLOGY (2016)
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Jon M. Hanifin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
John E. Harris et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaci et al.
LANCET (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Topical Ruxolitinib for the Treatment of Alopecia Universalis
Brittany G. Craiglow et al.
JAMA DERMATOLOGY (2016)
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Julian Mackay-Wiggan et al.
JCI INSIGHT (2016)
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis
David Roblin et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Commentary: IL-4 and IL-13 receptors and signaling
Sarah M. McCormick et al.
CYTOKINE (2015)
Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor
Masutaka Furue et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2015)
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia
Lisa Pieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis
Jacob P. Thyssen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Jennifer D. Hamilton et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1
Ferda Cevikbas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial
Masutaka Furue et al.
JOURNAL OF DERMATOLOGY (2014)
Opposing Immunomodulatory Roles of Prostaglandin D2 during the Progression of Skin Inflammation
Hana Sarashina et al.
JOURNAL OF IMMUNOLOGY (2014)
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing et al.
NATURE MEDICINE (2014)
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis
Mayte Suarez-Farinas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Antipruritic Effect of the Topical Phosphodiesterase 4 Inhibitor E6005 Ameliorates Skin Lesions in a Mouse Atopic Dermatitis Model
Naoto Ishii et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
Aman Samrao et al.
ARCHIVES OF DERMATOLOGY (2012)
Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin
Krisztina Szegedi et al.
EXPERIMENTAL DERMATOLOGY (2012)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Naresh Punwani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Antipruritic Effects of TRPV1 Antagonist in Murine Atopic Dermatitis and Itching Models
Jun-Won Yun et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Efficacy and Safety of Topical WBI-1001 in the Treatment of Atopic Dermatitis: Results From a Phase 2A, Randomized, Placebo-Controlled Clinical Trial
Robert Bissonnette et al.
ARCHIVES OF DERMATOLOGY (2010)
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections
Thomas R. Fritsche et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Byung Eui Kim et al.
CLINICAL IMMUNOLOGY (2008)
Structures and biological functions of IL-31 and IL-31 receptors
Qing Zhang et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2008)
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus
Thomas R. Fritsche et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D. Howell et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Effects of skin surface temperature on epidermal permeability barrier homeostasis
Mitsuhiro Denda et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase
Won-Sik Shim et al.
JOURNAL OF NEUROSCIENCE (2007)
IL-31: A new link between T cells and pruritus in atopic skin inflammation
E Sonkoly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity
HS Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
SR Dillon et al.
NATURE IMMUNOLOGY (2004)
Share Paper
